Arthritis Therapeutics Market: Numerous Product and Novel Drug Launches Leading to New Heights

The arthritis therapeutics market, characterized by healthy growth, is witnessing numerous promising pipeline projects and new product launches in parallel to increasing awareness campaigns run by public and private organizations. The patent expiration of blockbuster drugs is putting more pressure on manufacturers to develop effective versions of these drugs, which is projected to pave the way for the advancements of biosimilar products.

According to the Centers for Disease Control and Prevention (CDC) data published in 2018, ~54 Mn adults in the U.S. have been diagnosed with arthritis, and the number will grow to ~78 Mn by 2040. In this fast-paced era, individuals can’t afford to reduce their range of motion, which pertinently entails that those residing in developed countries are massively partaking in the diagnosis and treatment of arthritis as compared to those in developing countries. In the future, as the success of health awareness campaigns increases in developing countries, manufacturers in the arthritis therapeutics market will scramble towards these countries to leverage the first mover’s advantage.

arthritis therapeutics market infographic

To understand how our report can bring difference to your business strategy, Ask for a brochure

Perpetual Increase in Drug Prices to Impact Health of Arthritis Therapeutics Market

Despite the stronghold of disease-modifying antirheumatic drugs (DMARDs) in the arthritis therapeutics market, next gen antibody therapeutics are found to gain ground in recent times, on account of their higher efficiency. However, the efficiency of these drugs comes at a price, indeed a high one, ranging from US$ 1,000 to US$ 3,000 per month, which could hold back the sales potential of these drugs.

The price of Humira - a default drug for the treatment of arthritis - saw a steep increase in its price by 68.7% over the last five years, which equals to US$ 3,700 for a month-long supply. Also, the wholesale cost of the drug Enbrel has risen by 80.3% in the same time period, as found by Alliance of Community Health Plans. What’s more of an adoption concern for patients is the lack of discounts and deals, and the retail price further rises when they are distributed to retailers and pharmacies. Given the recommendation for a long-term course of arthritis treatment, high cost can affect the monthly budgets of patients, which could negatively impact sales in the arthritis therapeutics market space.

Request a sample to get extensive insights into the Arthritis Therapeutics Market

Parenteral Route to Grow as Preferable Drug-consumption Mode

As per the report, in 2019, the parenteral route of drug administration is projected to be used for ~83% cases for arthritis treatment, while in the remaining ~17% cases, the oral and topical route will be preferred. To put this data into perspective, parenteral administration possesses better control over the dose and frequency, thereby ensuring an improved treatment outcome as compared to oral therapeutics. These routes of drug administration, in turn, are also found to offer better bioavailability and metabolism avoidance. On the contrary, patients are liable to maintain a course of oral drugs on their own, and in cases where they miss out on popping a pill, recovery can take a longer time.

arthritis therapeutics market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Arthritis Therapeutics Market”

Analysts’ Opinion on Arthritis Therapeutics Market

Analysts of the report opine that, the arthritis therapeutics market will record 8.5% more sales in 2019 over 2018, and continue to advance at a CAGR of ~6% during 2019-2027. The high prevalence of arthritis that primarily weakens the joints and degrades the quality of life of patients, is projected to encourage more patients to avail proper treatment options. Given the growing demand, head-to-head trails to boost the efficacy profiles of drugs intensify the competition in the arthritis therapeutics market, and strategic partnership to target new markets backed by innovative product-level approaches will form a profitable deal for manufacturers.

It is worth noting that, retail pharmacies will take over ~78% sales of these therapeutics in the year 2019, which implies the need for market players to strengthen distribution partnerships with retailers of all scales.

Global Arthritis Therapeutics Market: Overview

  • The global arthritis therapeutics market was valued at ~US$ 43 Bn in 2018, and is projected to expand at a CAGR of ~6% from 2019 to 2027, to reach ~US$ 72.6 Bn by 2027.
  • Increasing incidence of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and other types of arthritis across the globe, is a major factor that is likely to fuel the global arthritis therapeutics market.
  • Ongoing arthritis clinical trials, increase in the geriatric population, rising investments in research & development, increasing demand for biologics, launching of novel products, and surge in mergers and strategic alliances are also anticipated to propel the growth of the global market.
  • Arthritis is an inflammatory joint condition, which causes pain and stiffness, and worsens with age. More than 100 types of arthritis exists, along with different causes and underlying infections. The common types of arthritis are rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
  • Several therapeutics and medications have been developed in recent years to relieve and treat the symptoms of arthritis. The most commonly used drugs belong to the drug class of TNF inhibitors, interleukin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other drugs. TNF inhibitors are widely utilized for the treatment of arthritis disorders. Arthritis is a highly underdiagnosed and undertreated medical condition, with a large number of patients unsatisfied with the current treatment options available. This offers significant opportunity to biopharmaceutical players operating in the arthritis therapeutics market to offer novel drugs. The under-penetration of biologic drugs in a majority of developed and emerging markets for the treatment of arthritis offers significant opportunities to global biopharmaceutical players.
  • A large number of both, small molecules and biologic products are under different phases of clinical trials. Leading companies have made significant investments in clinical R&D, and have established strategic partnerships and collaborations to accelerate new product development.

Global Arthritis Therapeutics Market: Key Segment

  • Based on type, the global arthritis therapeutics market has been categorized into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and others. Among these, the rheumatoid arthritis segment is the largest, and is expected to dominate the market during the forecast period. The high market share of the rheumatoid arthritis segment can be attributed to the availability of effective biologics for its treatment. The psoriatic arthritis segment is projected to grow at the highest pace during the forecast period, due to increasing number of psoriasis patients likely to develop psoriatic arthritis.
  • In terms of drug class, the global arthritis therapeutics market has been divided into TNF inhibitors, interleukin inhibitors, NSAIDs, corticosteroids, xanthine oxidase inhibitors, and others. The TNF inhibitors segment dominates the global market, owing to its higher efficacy rate as compared to other small molecules. Moreover, increasing investments toward the development of TNF inhibitor biologics are likely to drive the segment. The interleukin inhibitors segment is expected to expand at the highest CAGR, owing to ongoing clinical studies supporting their effectiveness, and quick adoption of interleukin inhibitors in gout, PsA, and RA indications.
  • On the basis of route of administration, the global arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for the largest share of the global market, and is expected to continue its dominance, owing to large volume prescriptions of biologic drugs administered through intravenous and subcutaneous injections.
  • Based on distribution channel, the global market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment holds a major market share, owing to the easy availability of biologics drugs in retail pharmacies, and increasing retail pharmacy stores across the globe.

Global Arthritis Therapeutics Market: Major Players

  • Key players operating in the global arthritis therapeutics market include
    • Novartis AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Pfizer Inc
    • Janssen Global Services
    • LLC (Johnson & Johnson)
    • F. Hoffmann-La Roche Ltd
    • Sanofi.
  • These players are focused on mergers & acquisitions, development of novel products, launch of biosimilars, and implementation of inorganic and inorganic growth strategies to strengthen their product portfolios and global footprint.
  • Moreover, companies are attracting investments for the research & development of arthritis drugs in order to improve patient care and remain competitive in the global market.

Arthritis Therapeutics Market – Scope of the Report

TMR’S report on the global arthritis therapeutics market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global market for the forecast period.

The report has been prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global arthritis therapeutics market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approach to study the various phenomena in the global market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the market. The next section of the global market report highlights key insights, which include the growing prevalence of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and other types, ongoing clinical trials and pipeline analysis, major arthritis brands in the market, and regulatory scenarios in the global market.

The report delves into the competitive landscape of the global arthritis therapeutics market. Key players operating in the global market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOTs are some of the attributes of players in the market profiled in this report.

Key Questions Answered in the Arthritis Therapeutics Market Report

  • How does the recent launching of novel and effective drugs provide scope of growth in the global market?
  • How are ongoing clinical trials for arthritis widening the scope for arthritis therapeutics?
  • How are various drug classes effective in the treatment of arthritis, and provide opportunities to key players for growth?
  • What are the revenue share projections of key segments under various criteria in the global market for the forecast period?
  • Which segment is likely to lead the market in terms of revenue by 2027?
  • How are changing regulatory scenarios, along with changing healthcare systems in developed and developing countries having an impact on the overall market?

Arthritis Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global arthritis therapeutics market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, and healthcare compliances laid down by accredited agencies in the purview of research in the global market. It is followed by market introduction, market dynamics, and an overview of the global market, which includes TMR analysis of the market drivers, restraints, and trends affecting the growth of the global arthritis therapeutics market. Furthermore, to understand the Y-o-Y trends of the market, a Y-o-Y analysis with elaborated insights on the same have been provided. The next section of the global arthritis therapeutics report highlights key insights, which include growing prevalence of arthritis disease across the globe, top analysis of key brands, pipeline analysis, and key industry developments in the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of the actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period. To ascertain the size of the global arthritis therapeutics market in terms of value, revenue generated by key arthritis drugs manufacturers has been mapped. The forecast presented here assesses the total revenue generated in the market.

Global Arthritis Therapeutics Market – Segmentation 

Type

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Gout
  • Others

Drug Class

  • TNF Inhibitors
  • Interleukin Inhibitors
  • NSAIDs
  • Corticosteroids
  • Xanthine Oxidase Inhibitors
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North
  • America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4.  Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Arthritis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Arthritis Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key product/brand Analysis

    5.2. Pipeline Analysis

    5.3. Disease Prevalence & Incidence Rate globally with key countries

    5.4. Regulatory Scenario by Region/globally

6. Global Arthritis Therapeutics Market Analysis and Forecast, By Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

        6.3.1. Rheumatoid Arthritis

        6.3.2. Osteoarthritis

        6.3.3. Psoriatic Arthritis

        6.3.4. Gout

        6.3.5. Others

    6.4. Market Attractiveness By Type

7. Global Arthritis Therapeutics Market Analysis and Forecast, By Drug Class 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        7.3.1. TNF Inhibitors

        7.3.2. Interleukin Inhibitors

        7.3.3. NSAIDs

        7.3.4. Corticosteroids

        7.3.5. Xanthine Oxidase Inhibitors

        7.3.6. Others

    7.4. Market Attractiveness By Drug Class 

8. Global Arthritis Therapeutics Market Analysis and Forecast, By Route of Administration 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        8.3.1. Oral

        8.3.2. Parenteral

        8.3.3. Topical 

    8.4. Market Attractiveness By Route of Administration 

9. Global Arthritis Therapeutics Market Analysis and Forecast, By Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness By Distribution Channel

10. Global Arthritis Therapeutics Market Analysis and Forecast, By Region 

    10.1. Key Findings

    10.2. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Region

        10.2.1. North America

        10.2.2. Europe 

        10.2.3. Asia Pacific

        10.2.4. Latin America 

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Country/Sub-region /Region

11. North America Arthritis Therapeutics Market Analysis and Forecast

    11.1.  Introduction

        11.1.1.  Key Findings

    11.2. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        11.2.1. Rheumatoid Arthritis

        11.2.2. Osteoarthritis

        11.2.3. Psoriatic Arthritis

        11.2.4. Gout

        11.2.5. Others

    11.3.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        11.3.1. TNF Inhibitors

        11.3.2. Interleukin Inhibitors

        11.3.3. NSAIDs

        11.3.4. Corticosteroids

        11.3.5. Xanthine Oxidase Inhibitors

        11.3.6. Others

    11.4.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        11.4.1. Oral

        11.4.2. Parenteral

        11.4.3. Topical 

    11.5. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Drug Class

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country/Sub-region 

12. Europe Arthritis Therapeutics Market Analysis and Forecast

    12.1.  Introduction

        12.1.1.  Key Findings

    12.2. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        12.2.1. Rheumatoid Arthritis

        12.2.2. Osteoarthritis

        12.2.3. Psoriatic Arthritis

        12.2.4. Gout

        12.2.5. Others

    12.3.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        12.3.1. TNF Inhibitors

        12.3.2. Interleukin Inhibitors

        12.3.3. NSAIDs

        12.3.4. Corticosteroids

        12.3.5. Xanthine Oxidase Inhibitors

        12.3.6. Others

    12.4.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        12.4.1. Oral

        12.4.2. Parenteral

        12.4.3. Topical 

    12.5. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Country/Sub-region, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Drug Class

        12.7.3. By Route of Administration

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region 

13. Asia Pacific Arthritis Therapeutics Market Analysis and Forecast

    13.1.  Introduction

        13.1.1.  Key Findings

    13.2. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        13.2.1. Rheumatoid Arthritis

        13.2.2. Osteoarthritis

        13.2.3. Psoriatic Arthritis

        13.2.4. Gout

        13.2.5. Others

    13.3.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        13.3.1. TNF Inhibitors

        13.3.2. Interleukin Inhibitors

        13.3.3. NSAIDs

        13.3.4. Corticosteroids

        13.3.5. Xanthine Oxidase Inhibitors

        13.3.6. Others

    13.4.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        13.4.1. Oral

        13.4.2. Parenteral

        13.4.3. Topical 

    13.5. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Drug Class

        13.7.3. By Route of Administration

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region 

14. Latin America Arthritis Therapeutics Market Analysis and Forecast

    14.1.  Introduction

        14.1.1.  Key Findings

    14.2. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        14.2.1. Rheumatoid Arthritis

        14.2.2. Osteoarthritis

        14.2.3. Psoriatic Arthritis

        14.2.4. Gout

        14.2.5. Others

    14.3. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        14.3.1. TNF Inhibitors

        14.3.2. Interleukin Inhibitors

        14.3.3. NSAIDs

        14.3.4. Corticosteroids

        14.3.5. Xanthine Oxidase Inhibitors

        14.3.6. Others

    14.4.  Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        14.4.1. Oral

        14.4.2. Parenteral

        14.4.3. Topical 

    14.5. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Drug Class

        14.7.3. By Route of Administration

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region 

15. Middle East & Africa Arthritis Therapeutics Market Analysis and Forecast

    15.1.  Introduction

        15.1.1.  Key Findings

    15.2. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        15.2.1. Rheumatoid Arthritis

        15.2.2. Osteoarthritis

        15.2.3. Psoriatic Arthritis

        15.2.4. Gout

        15.2.5. Others

    15.3.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        15.3.1. TNF Inhibitors

        15.3.2. Interleukin Inhibitors

        15.3.3. NSAIDs

        15.3.4. Corticosteroids

        15.3.5. Xanthine Oxidase Inhibitors

        15.3.6. Others

    15.4.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        15.4.1. Oral

        15.4.2. Parenteral

        15.4.3. Topical 

    15.5. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Market Attractiveness Analysis

        15.7.1. By Type

        15.7.2. By Drug Class

        15.7.3. By Route of Administration

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region 

16. Competition Landscape

    16.1. Market Share Analysis By Company (2018)

    16.2.  Company Profiles

        16.2.1. Novartis AG

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Financial Overview      

            16.2.1.3. Product Portfolio

            16.2.1.4. Strategic Overview

            16.2.1.5. SWOT Analysis

        16.2.2. Eli Lilly and Company

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Financial Overview      

            16.2.2.3. Product Portfolio

            16.2.2.4. Strategic Overview

            16.2.2.5. SWOT Analysis

        16.2.3. Amgen, Inc.

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Financial Overview      

            16.2.3.3. Product Portfolio

            16.2.3.4. Strategic Overview

            16.2.3.5. SWOT Analysis

        16.2.4. Merck & Co., Inc.

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Financial Overview      

            16.2.4.3. Product Portfolio

            16.2.4.4. Strategic Overview

            16.2.4.5. SWOT Analysis

        16.2.5. Bristol-Myers Squibb Company

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Financial Overview      

            16.2.5.3. Product Portfolio

            16.2.5.4. Strategic Overview

            16.2.5.5. SWOT Analysis

        16.2.6. Pfizer, Inc. 

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Financial Overview      

            16.2.6.3. Product Portfolio

            16.2.6.4. Strategic Overview

            16.2.6.5. SWOT Analysis

        16.2.7. AbbVie, Inc.

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Financial Overview      

            16.2.7.3. Product Portfolio

            16.2.7.4. Strategic Overview

            16.2.7.5. SWOT Analysis

        16.2.8. Janssen Global Services, LLC (Johnson & Johnson)

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Financial Overview      

            16.2.8.3. Product Portfolio

            16.2.8.4. Strategic Overview

            16.2.8.5. SWOT Analysis

        16.2.9. F. Hoffmann-La Roche Ltd

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Financial Overview      

            16.2.9.3. Product Portfolio

            16.2.9.4. Strategic Overview

            16.2.9.5. SWOT Analysis

        16.2.10. Sanofi

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Financial Overview      

            16.2.10.3. Product Portfolio

            16.2.10.4. Strategic Overview

            16.2.10.5. SWOT Analysis

List of Tables

Table 01: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 02: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 03: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 04: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

Table 07: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration,

Table 09: North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 10: North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027

Table 11: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

Table 12: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 14: Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

Table 16: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 17: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 19: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

Table 21: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

Table 22: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 24: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 25: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

Table 26: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

Table 27: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 28: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 29: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 30: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Arthritis Therapeutics Market Snapshot

Figure 02: Global Arthritis Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 03: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017?2027

Figure 04: Global Arthritis Therapeutics Market Value Share (%), by Type (2018)

Figure 05: Global Arthritis Therapeutics Market Value Share (%), by Route of Administration (2018)

Figure 06: Global Arthritis Therapeutics Market Value Share (%), by Drug Class (2018)

Figure 07: Global Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2018)

Figure 08: Global Arthritis Therapeutics Market Value Share (%), by Region (2018)

Figure 09: Global Arthritis Therapeutics Market Value Share Analysis, by Type, 2018 and 2027

Figure 10: Global Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 11: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Rheumatoid Arthritis, 2017–2027

Figure 12: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Osteoarthritis, 2017–2027

Figure 13: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Psoriatic Arthritis, 2017–2027

Figure 14: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gout, 2017–2027

Figure 15: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

Figure 16: Global Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 17: Global Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 18: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017–2027

Figure 19: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2017–2027

Figure 20: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by NSAIDs, 2017–2027

Figure 21: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017–2027

Figure 22: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Xanthine Oxidase Inhibitors, 2017–2027

Figure 23: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

Figure 24: Global Arthritis Therapeutics Market Value Share(%), by Route of Administration, 2018 and 2027

Figure 25: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2017–2027

Figure 26: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2017–2027

Figure 27: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2017–2027

Figure 28: Global Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 29: Global Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 30: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017–2027

Figure 31: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017–2027

Figure 32: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017–2027

Figure 33: Global Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 34: Global Arthritis Therapeutics Market Value Share Analysis, by Region 2018 and 2027

Figure 35: Global Arthritis Therapeutics Market Attractiveness, by Region, 2019–2027

Figure 36: North America Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 37: North America Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

Figure 38: North America Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 39: North America Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

Figure 40: North America Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 41: North America Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 42: North America Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 43: North America Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 44: North America Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 45 : North America Arthritis Therapeutics Market Value Share (%), By Country/Sub-region , 2018 and 2027

Figure 46: North America Arthritis Therapeutics Market Attractiveness, By Country/Sub-region , 2019–2027

Figure 47: Europe Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 48: Europe Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

Figure 49: Europe Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 50: Europe Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

Figure 51: Europe Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 52: Europe Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 53: Europe Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 54: Europe Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 55: Europe Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 56: Europe Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

Figure 57: Europe Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

Figure 58: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 59: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

Figure 60: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 61: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

Figure 62: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 63: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 64: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 65: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 66: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 67 : Asia Pacific Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

Figure 68: Asia Pacific Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

Figure 69: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 70: Latin America Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

Figure 71: Latin America Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 72: Latin America Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

Figure 73: Latin America Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 74: Latin America Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 75: Latin America Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 76: Latin America Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 77: Latin America Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 78 : Latin America Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

Figure 79: Latin America Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

Figure 80: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 81: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

Figure 82: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

Figure 83: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

Figure 84: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 85: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 86: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 87: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 88: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 89: Middle East & Africa Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Arthritis Therapeutics Market